IP Library Granted Patent US 8,563,708
Granted Patent B2
US 8,563,708 · App. 11/837,487 · Granted Oct 22, 2013

Methods and compositions involving miRNA and miRNA inhibitor molecules

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,563,708
App. No.
11/837,487
Granted
Oct 22, 2013
Kind
B2
Abstract

The present invention concerns methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules. Moreover, the present invention concerns methods and compositions for identifying miRNAs with specific cellular functions that are relevant to therapeutic, diagnostic, and prognostic applications wherein synthetic miRNAs and/or miRNA inhibitors are used in library screening assays.

Claims (15)

1. A synthetic RNA molecule comprising two polynucleotides each between 17 and 25 residues in length comprising

a) a first polynucleotide comprising an miRNA region whose sequence from 5′ to 3′ is identical to a mature miRNA sequence, and

b) a second polynucleotide comprising a complementary region whose sequence from 5′ to 3′ is 100% complementary to the miRNA sequence,

wherein i) the 5′ terminus of the second polynucleotide is replaced with a lower alkylamine group and/or ii) there are one or more sugar modifications with a 2′ oxygen-methyl (2′O-Me) in the first or last 1 to 6 residues of the second polynucleotide.

2. The RNA molecule of claim 1 , comprising one or more sugar modifications in the first 1 to 6 residues of the second polynucleotide.

3. The RNA molecule of claim 1 , comprising one or more sugar modifications in the last 1 to 6 residues of the second polynucleotide.

4. The RNA molecule of claim 1 , comprising one or more sugar modifications in the first or last 2 to 4 residues of the second polynucleotide.

5. The RNA molecule of claim 4 , comprising more than one sugar modification in the first or last 2 to 4 residues of the second polynucleotide.

6. The RNA molecule of claim 1 , comprising noncomplementarity between one or more nucleotides in the last 1 to 5 residues at the 3′ end of the complementary region and the corresponding nucleotides in the complementary region.

7. The RNA molecules of claim 6 , wherein there is noncomplementarity with at least 2 nucleotides in the complementary region.

8. The RNA of claim 1 , wherein the RNA molecule further comprises a flanking region of 1-5 nucleotides at either the 5′ or 3′ region of either or both polynucleotides.

9. A synthetic RNA molecule comprising two polynucleotides each between 17 and 25 residues in length comprising

a) a first polynucleotide comprising an miRNA region whose sequence from 5′ to 3′ is identical to a mature miRNA sequence, and

b) a second polynucleotide comprising a complementary region whose sequence from 5′ to 3′ is 100% complementary to the miRNA sequence,

wherein the 5′ terminus of the second polynucleotide is replaced with a lower alkylamine group.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 13, 2015
From: BROWN, DAVID; FORD, LANCE; CHENG, ANGIE; JARVIS, RICH; BYROM, MIKE; OVCHARENKO, DMITRIY; DEVROE, ERIC; KELNAR, KEVIN
To: AMBION, INC.
Reel/Frame 035631/0268 →
MERGER Recorded May 13, 2015
From: AMBION, INC.
To: APPLERA CORPORATION
Reel/Frame 035631/0500 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 13, 2015
From: APPLERA CORPORATION
To: ASURAGEN, INC.
Reel/Frame 035631/0703 →